Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age \>=18 and \<= 80years~* consent obtained from patient~* effective female contraceptive method for women in procreate age~* new case of pemphigus vulgaris (PV) or pemphigus foliaceus (PF)~Exclusion Criteria:~* pemphigus vulgaris (PV) or pemphigus foliaceus (PF) treated~* pregnant woman or nursing mother~* woman able to have a baby and without contraception during the clinical trial period~* age \< 18 or \> 80~* karnovsky \< 50%~* serious antecedents of allergy or anaphylactic reaction with human monoclonal antibody~* patient with depletion lymphocytic treatment in the next month~* unstable angina or ischemic heart disease~* cardiac insufficiency~* cardiac rhythm trouble uncontrolled~* positive HIV serology~* positive hepatitis B and / or C serology~* no consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: EXPERIMENTAL): None
- Corticotherapy (Type: ACTIVE_COMPARATOR): General Corticotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).